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Methods: We performed a retrospective chart review to
identify patients with excessive weight gain while under-
going ﬁlgrastim-induced PBSC mobilization. The primary
endpointwas todetermine the incidence of> 2% bodyweight
gain during PBSC mobilization. Secondary endpoints were to
identify the factors that predict abnormal weight gain and to
evaluate its impact on NRM and OS after auto-HCT.
Results: We identiﬁed 95 patients with AL who underwent
PBSC mobilization and collection followed by auto-HCT
between 2002 and 2011. Thirty-nine (41%) patients had renal
involvement, 12 patients had cardiac involvement (12.6%)
and 5 (5.2%) patients had liver involvement. Seven patients
required hospitalization during PBSC mobilization due to
ﬂuid overload. Six patients died within a year of auto-HCT
non-relapse causes with 1-year NRM of 6.3%. Median follow
up after auto-HCT in surviving patients was 13 months.
Kaplan-Meier estimates of median OS was 73 months. Forty-
nine (51.5%) patients had >2% weight gain due to ﬂuid
overload during PBSCmobilization, while 46 patients (48.5%)
had 2 % weight gain. More patients with >2% weight gain
required diuretics (34 vs. 10: P < .0001) and had lower
median serum albumin (2.8 vs. 3.75 g/dl, P < 0.0001). There
were no signiﬁcant differences in baseline serum creatinine,
GFR, alkaline phosphatase, ﬁlgrastim dose, urine total
protein, BNP, ejection fraction, cardiac septal thickness,
number of organs involved, or cardiac or renal involvement
between the two groups. 1-year NRM was 6.1 vs. 8.6 % in
patients with >2% or 2% weight gain (p¼0.70). There was
no signiﬁcant difference in median OS survival between
patients with > or 2% weight gain (p¼0.54: Figure 1).
Conclusion: Patients with AL and low baseline serum
albumin are at higher risk of ﬂuid retention and excessive
weight gain that may require hospitalization. However, in
our study, this weight gain did not have an adverse impact on
NRM or OS.Figure 1.139
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The aim of this case report is to describe the use of plerixafor
in a patient with multiple myeloma and dialysis-dependantrenal failure. A 43-year-old man with multiple myeloma and
dialysis-dependent renal failure was evaluated for an autol-
ogous stem cell transplant (ASCT). Following Stem cell
mobilisation with cyclophosphamide 1.5g/m2 and 9 doses of
granulocyte colony-stimulating factor (G-CSF) 10mcg/kg/day
the patient's pre apheresis CD34+ count was inadequate at
2.18 cells/mL. Perixafor was prescribed to achieve stem cell
mobilisation. There is no dose recommendation for plerixafor
in patients with CrCl< 20mL/min or those on dialysis. In this
patient we used 0.16mg/kg/day dose, which is the dose rec-
ommended for patients with CrCl 20-50mL/min. The ﬁrst
plerixafor dose was given subcutaneously post-dialysis 8
hours before apheresis and the second dose was given the
next day 9 hours prior to second apheresis session. The pre-
apheresis CD34+ countwas 11.99 and8.82 cells/mLwith a total
White cell count of 22.2 and 17.3 x 10^9/L after the ﬁrst and
second doses respectively. The patient underwent stem cell
collectionvia the SpectraOptia cell separatorwith a total yield
of 2.4 x 106 cells/kg. There were no observed toxicities with
plerixafor. InMay 2012, 6weeks after stem cell collection, the
patient underwent ASCT with reduced dose of Melphalan
140mg/m2. Neutrophil engraftment occurred at day +11, the
patientwasdischarged at day+16. Todate thepatient remains
well and in remission. This case report illustrates that pler-
ixafor can safely and effectively be used to mobilise adequate
stem cells in multiple myeloma patients with end stage renal
failure. Information regarding dosing and safety of plerixafor
in dialysis patients remains limited,wehope that information
provided by this report would be useful for other clinicians
who are considering the use of plerixafor in this setting.141
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Autologous stem cell transplantationplays a critical role in the
management of patients with hematologic malignancies
such as multiple myeloma and malignant lymphoma. The
minimum number of CD34 positive cells required for trans-
plantation is believed to be 2.0106 cells/kg. Up to 20% of the
patients, however, fail to reach the number after a single
collection attempt and require multiple aphereses to obtain
a sufﬁcient number of stem cells. To predict the outcome of
mobilization, several pre-mobilization factors have been
investigated, including peripheral blood CD34+ cell count at
the time of harvest, but little is as yet known about the
signiﬁcance of serum lactate dehydrogenase (LDH). We,
therefore, sought to evaluate the predictive potential of serum
LDH for the autologous stem cell yield. Peripheral blood stem
cell mobilization attempts were made from April 2002 to
March 2012 for 55 consecutive patients of hematologic
disorders. Primary diagnosis of our patients and their mobi-
lization chemotherapy regimens are shown in Table 1. All
patient received G-CSF (ﬁlgrastim 400mg/sq/day or lenogras-
tim 10mg/kg/day subcutaneously). None was mobilized with
G-CSF alone. Aphereseswere repeated until the total stem cell
yield exceeded 2106cells/kg, for maximum 3 consecutive
days. Forty-four patients successfully produced the sufﬁcient
numberof stemcells,while 11patients failed (poormobilizer).
